Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: ValuEngine, Inc.
$49.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

MusclePharm Corp raises FY 2014 revenue outlook; lowers FY 2014 EPS outlook


Monday, 5 May 2014 08:00am EDT 

MusclePharm Corp:Revises FY 2014 net sales of about $165 - $175 mln.Expects FY 2014 diluted earnings per share in the range of $0.41 - $0.51.FY 2014 revenue of $150 mln - Thomson Reuters I/B/E/S. 

Company Quote

4.59
0.45 +10.87%
20 Apr 2015